A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-15

Study Completion Date

2022-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

NCT04501094

Urothelial Cancer

TERMINATED PHASE2

Bintrafusp Alfa Program Rollover Study

NCT05061823

Lung Cancer Cancer

COMPLETED PHASE3

SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial

NCT00578526

Urothelial Cancer Bladder Cancer Adult

COMPLETED PHASE2

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

NCT01118039

Bladder Cancer Transitional Cell Cancer of the Renal Pelvis and Ureter Urethral Cancer

UNKNOWN PHASE2

A Study of MFA-370 in Patients with Metastatic Urothelial Cancer

NCT05390645

Metastatic Urothelial Cancer

WITHDRAWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is a single arm study.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

This is an open label study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants receiving bintrafusp alfa

Participants will receive bintrafusp alfa.

Group Type EXPERIMENTAL

Bintrafusp alfa

Intervention Type DRUG

Participants will receive bintrafusp alfa.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bintrafusp alfa

Participants will receive bintrafusp alfa.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants can give signed informed consent/assent.
* Participants with histologically confirmed locally advanced or metastatic or locally advanced/unresectable urothelial carcinoma (including renal, pelvis, ureter, urinary bladder, urethra).
* Able to provide, a tumor tissue sample collected during screening and prior to administration of bintrafusp alfa.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
* Participants with adequate organ system functions.
* Life expectancy of at least 12 weeks.
* A female is eligible if she is not pregnant or breastfeeding.

Exclusion Criteria

* Active brain and/or leptomeningeal disease that is symptomatic or requires therapeutic intervention. Participants with asymptomatic central nervous system (CNS) metastases who are clinically stable as demonstrated by serial brain images and have no requirement for corticosteroids for at least 14 days prior to enrollment are eligible.
* History of malignancy other than urothelial cancer within the last 3 years except for localized tumors that have been treated with curative intent or have not required therapy in the past 2 years. (e.g., resected non-melanoma skin cancer).
* No more than 2 lines of systemic therapy for the treatment of metastastic disease. If the most recent therapy was not a platinum-based regimen, the participant must have progressed on or after that therapy.
* Cirrhosis or current unstable liver or biliary disease per investigator assessment.
* Current pneumonitis or history of non-infectious pneumonitis that required systemic immunosuppressive treatment.
* Active autoimmune disease that required systemic immunosuppressive treatment within the past 2 years.
* Received prior allogeneic/autologous bone marrow or solid organ transplant.
* Receiving systemic corticosteroids (\>10 milligrams \[mg\] daily oral prednisone or equivalent) or other immunosuppressive agent within 7 days prior to study treatment. Inhaled or topical steroids are permitted.
* Known severe hypersensitivity reactions to monoclonal antibodies or any ingredient used in the study treatment formulation (Grade \>=3 National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] version 5.0).
* Active infection requiring systemic therapy.
* Received any live vaccine within 30 days prior first dose of intervention.
* Known history of positive test for human immunodeficiency virus (HIV) with the exception of participants with cluster of differentiation 4 (CD4) + T-cell (CD4+) counts \>=350 cells per microliter (cells /uL) and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.
* Active hepatitis B virus (HBV) (HBV surface antigen-positive).
* Active hepatitis C virus (HCV) infection, or positive HCV antibody, with the exception of participants that 1. Have HCV viral load below the limits of quantitation and 2. Completed curative antiviral therapy or are receiving and compliant with antiviral therapy.
* History or evidence of cardiac abnormalities within the 6 months prior to first dose of intervention.
* Participants with history of bleeding diathesis or recent major bleeding events considered by the Investigator as high risk for investigational drug treatment are also excluded.
* Any other serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results.
* Received prior systemic anti-cancer therapy within 2 weeks prior to study treatment.
* Received prior therapy with an anti-programmed death 1 (PD-1), anti-programmed death Ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
* Received prior therapy targeting transforming growth factor (TGF) beta - (e.g., Galunistertib).
* Received radiation therapy (or other non-systemic disease therapy) within 2 weeks prior to study treatment.
* Undergone major surgery within 4 weeks prior to administration of study treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No